To ensure this strategy was also effective in patient-derived cells, we tested these bicistronic vectors in HSPCs derived from patients with SCD, this time comparing them with a therapeutic full-length HBB transgene14. This evidence concerns the gene HBB and Schnyder corneal dystrophy.